curriculum vitae for carl-david agardh - Lund University Diabetes ...

CURRICULUM VITAE FOR CARL-DAVID AGARDH
Name: Carl-David Agardh
Address:
Unit on Vascular Diabetic Complications
CRC, entrance 72, 92;12
Lund University
Skåne University Hospital
SE-205 02 Malmö
Sweden
Phone: 0705-571245
Fax: +46 40 39 12 22
E-mail: carl-david.agardh@med.lu.se
EDUCATION
1992 Specialist in Endocrinology
1982 Docent in Internal Medicine
1982 Specialist in Internal Medicine
1981 Ph.D., University of Lund, Lund, Sweden
1974 M.D., Karolinska Institute, Stockholm, Sweden
1970 Bachelor of Science in Medicine, Karolinska Institute, Stockholm, Sweden
POSITIONS
2009 (Apr/May) Visiting Professor, Harvard Medical School, Boston, USA
2005- Affiliate Clinical Professor, College of Medicine, University of Arizona,
Tucson, Arizona, USA
1999- Professor, Lund University, Lund, Sweden, Hospital MAS, Malmö, Sweden
1999- Medical Director, University Hospital MAS, Malmö, Sweden
1998-
Chief Consultant, Department of Endocrinology, University, MAS, Malmö, Sweden
1997 Visiting Associate Professor, Harvard Medical School, Joslin Center,Boston, USA
1995-1997 Deputy Chief of Staff, University Hospital, Lund, Sweden
1990-1995 Deputy Chief of Medicine, University Hospital, Lund, Sweden
1984-1994 Chief, Diabetes Section, Department of Internal Medicine, University Hospital,
Lund Sweden

1984 Visiting Associate, Diabetes Branch, National Institute of
Arthritis, Diabetes, Digestive and Kidney Disease, National
Institutes of Health, Bethesda, Maryland, USA
1982-1983 Fogarty Visiting Fellow, Diabetes Branch, National Institute of
Arthritis, Diabetes, Digestive and Kidney Disease, National
Institutes of Health, Bethesda, Maryland, USA
1977-1981 Research Fellow, Laboratory for Expermimental Brain Research,
University of Lund, Lund, Sweden
AWARDS
1992 The Quality Price of the year. How to prevent blindness in
diabetes. Lund University Hospital
1988 Odd Fellow Ordens Award in Medical Research
1984 Pedagogen. The teacher of the Year, University of Lund, Lund, Sweden
1981 Holger Crafoord Award in Medical Research
SOCIETIES
Swedish Medical Association
The Swedish Society of Medicine
American Diabetes Association, Inc
European Association for the Study of Diabetes
International Diabetes Federation
Scandinavian Society for the Study of Diabetes
Swedish Society of Internal Medicine
The Endocrine Society (elected)
Swedish Society for Diabetology
Swedish Diabetes Federation
Kungliga Fysiografiska Sällskapet i Lund (elected)
The Association for Research in Vision and Ophthalmology

RESEARCH PUBLICATIONS
193. Lindholm E, Bakhtadze E, Cilio CM, Agardh E, Groop L, Agardh C-D: Association
between LTA, TNF and AGER polymorphisms and late diabetic complications. PLOS ONE,
3:e2546, 2008.
194. Gustavsson C, Agardh E, Bengtsson B, Agardh C-D: TNF-α is an independent serum
marker for proliferative retinopathy in type 1 diabetic patients. Journal of Diabetes and Its
Complications. 22:309-316, 2008.
195. Fosmark DS, Borg MP, Jensen A-B, Agardh E, Agardh C-D, Hansson KF: Increased
retinopathy occurance in type 1 diabetes patients with increased serum levels of the
advanced glycation endproduct hydroimidazolone. Acta Ophthalmologica Scandinavica,
[Epub ahed of print], 2008.
196. Bakhtadze E, Cervin C, Lindholm E, Borg H, Nilsson P, Arnqvist HJ, Bolinder J, Eriksson
JW, Gudbjörnsdottir S, Nyström L, Agardh C-D, Landin-Olsson M, Sundkvist G, Groop L:
Common variants in the TCF7L2 gene help to differentiate autoimmune from nonautoimmune
diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic
patients. Diabetologia, 51:2224-2232, 2008.
197. Chaturvedi N, et al., for the Direct Programme Study Group* (Agardh C-D, National
Coordinator, Sweden). Effect of candersartan on prevention (DIRECT - Prevent 1) and
progression (DIRECT - Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled
trials. Lancet 372:1394-1402, 2008.
198. Sjölie Ø A, et al., for the DIRECT programme study Group* (C-D Agardh, National
coordinator, Sweden). Effect of candersartan on progression of retinopathy in type 2
diabetes (DIRECT-Protect 2): a randomised placebo-kontrolled trial. Lancet 372:1385-1393,
2008.
199. Khatibi A, Agardh C-D, Lidfeldt J, Samsioe G. Nonhormonal drug usage and its relation to
androgens in perimenopausel women: a population based study of Swedish women. The
Women´s Health in the Lund Area (WHILA) Study. Menopause. 2009 jan 21, [Epub ahed
of print].
200. Agardh D, Björck S, Agardh C-D, Lidfeldt J: Ceoliac disease specific tissue
transglutaminase autoantibodies are associated with osteoporosis and related fractures in
middle-aged women. Scandinavian Journal of Gastroenterology. 44:571, 2009.
201. Gustavsson C-G, Agardh C-D: Inflammatory activity increases with haemoglobin A1c in
patients with acute coronary syndrome. Scandinavian Cardiovascular Journal. 2009 Mar
16:1-6, [Epub ahed of print].
202. Papadopoulou A, Lynch KF, Shaat N, Nilsson A, Lernmark B, Berntorp K, Ivarsson SA,
Agardh C-D, Lernmark Å: On behalf of the DiPis Study Group. The type 1 diabetes
protective HLA-DQB1*0602 allele is less frequent in gestational diabetes mellitus.
Diabetologia. 2009 Apr 4 [Epub ahed of print].
203. Agardh C-D , Lynch K, Palmér M, Link K, Lernmark Å. GAD65 vaccination: 5 years of
follow-up in a randomised dose escalating study in adult-onset autoimmune diabetes.
Diabetologia. 2009 Apr 30 [Epub ahed of print].

204. Holm BC, Lindholm E, Bakhatadze E, Kalis M, Åkesson C, Agardh C-D, Cilio CM:
Association of FOXP3 polymorphisms with GAD 65 autoantibodies in type 1diabetes.
Submitted.
205. Nilsson-Berglund LM, Nilsson-Öhman J, Sigvardsson M , Zetterqvist AV, Gonzáles Bosc
LV, Smith M-L, Agardh E, Nordin-Fredriksson G, Agardh C-D, Nilsson J,
Wanhoff BR, Hultgårdh-Nilsson A, Gomez MF. Nucelar factor of activated T-cells
regulates osteopontin expression in smooth muscle in response to diabetes-induced
hyperglycemia. Submitted.
206. Agardh C-D, Agardh E, Obrosova IG, Smith M-L: The aldos reductase inhibitor fidarestat
suppresses ischemia-reperfusion induced inflammatory response in rat retina. Submitted.
207. Nilsson-Öhman J, Nordin Fredrikson G, Gustavsson C, Nilsson LM, Bengtsson E, Smith M-
L, Agardh C-D, Agardh E, Jovinge S, Gomez M, Nilsson J. Tumor necrosis factor-α does
not mediate diabetes-induced vascular inflammation in mice. Submitted.
208. Papadopoulou A, Lynch K, Shaat N, Håkansson R, Lernmark B, Ivarsson S-A, Berntorp K,
Agardh C-D, Lernmark Å.: Transcription factor 7-like 2 (TCF7L2) gene polymorphisms is
a marker of non-autoimmune gestational diabetes mellitus. Submitted.
209. Bakhtadze E, Cervin C, Lindholm E, Lyssenko V, Borg H, Nilsson P, Arnqvist HJ, Bolinder
J, Eriksson JW, Gudbjörnsdottir S, Nyström L, Agardh C-D, Landin-Olsson M, Groop LC:
Prevalence of common variants in novel type 2 diabetes genes in young and middle-aged
patients with autoimmune and non-autoimmune diabetes. Submitted.
210. Rignell-Hydbom A, Lidfeldt J, Kiviranta H, Rantakokko P, Samsioe G, Agardh C-D,
Rylander L: Persistent organochlorine pollutants: A novel risk factor for type 2 diabetes.
Submitted.
211. Hampe C, Oak S, Thi Phan T-H, Hirsch IB, Agardh C-D, Cilio CM, Lethagen Å, Lynch K,
Lernmark Å, Barnes J, Warsen A, Palmer JP, Brooks-Worrell B. The lack of GAD65
autoantibody-specific anti-idiotypic antibodies precedes islet autoimmunity in type 2
diabetes patients. Submitted.
212. Gustavsson C, Agardh E, Gomez M, Nilsson J, Agardh C-D: Uneven VCAM-1-expression
is associated with leukocytosis in diabetic retina from genetically modified mice and is
influenced by TNF-alfa. Submitted.
213. Sami FV, Oak S, Radtke J, Lernmark A, Lynch K, Agardh C-D, Cilio CM, Lethagen AL,
Ortqvist E, Landin-Olsson M, Thorn C, Hampe CS. ZnT8 autoantibodies are found in the
majority of young T1D patients and their titers decline rapidly after onset. Submitted.
214. Gustavsson C, Agardh E, Nilsson J, Gomez M, Agardh C-D. Vascular cellular
adhesion molecule-1 (VCAM-1) expression and CD45 positive leukocytes in retina from
diabetic and genetically modified (ApoE-/-, TNF-α-/- and ApoE-/-/ TNF-α-/-) mice. Submitted.